Henlius Announces 2020 Annual Results

In the application of advanced production technology, the company continues to promote the development and industrialization of continuous flow technology, and completed the construction, debugging and verification of the continuous production pilot plant at the end of 2020
.
Next, the company will continue to forward-looking design and production optimization process, carry out lean production capacity layout, and establish a domestic leading position by using total production capacity and process technology advantages
.

Strengthen foreign cooperation: join hands with strategic partners to lay out the global market

In 2020, Fuhong Henlius reached the initial and further cooperation with Mabxience and Accord respectively, granting each other the exclusive development and commercialization rights of Hanquyou®, and successfully expanded the commercialization of Hanquyou® to mainstream biological drugs in Europe and the United States.
Market
.
At the same time, Henlius is actively exploring the efficacy of bevacizumab HLX04-O (recombinant anti-VEGF humanized monoclonal antibody injection) in wet age-related macular degeneration (wAMD) and other eye diseases.
This indication The patient population is wide, but medication is not yet universal
.
In 2020, the company and Essex Biosciences reached a cooperation to jointly develop HLX04-O, granting each other the exclusive license to register, develop, produce and commercialize ophthalmic indications on a global scale.
Both parties will focus on HLX04-O ophthalmic indications in China , Australia, the European Union, the United States and other countries and regions carry out international multi-center clinical trials, and rely on the research results to simultaneously apply for listing in many countries and regions around the world
.
At present, HLX04-O has passed the clinical trial registration of the Australian Drug Administration (TGA) and the US FDA clinical trial approval.
The international multi-center phase III clinical study of the project will be launched in the near future
.
In the future, Henlius will continue to promote the company's internationalization process in an all-round way, accelerate the expansion of the international market, introduce products and foreign licenses at the same time, and cooperate with global partners to jointly develop and expand the global coverage of products
.

In the future, Henlius will continue to focus on excellence in commercialization, continue to deepen the value of listed biosimilar products, and consolidate its leading position in biosimilars
.
At the same time, the company is committed to longer-term strategic goals, starting from the unmet clinical needs of patients, accelerating innovation and upgrading, improving R&D efficiency, while continuously improving internal innovation R&D capabilities, actively introducing innovative and high-quality products through strategic cooperation, "internal and external "Part-time" creates an increasingly mature diversified innovation pipeline to provide more patients with affordable and high-quality innovative biological drugs
.